SCHEMBL4089129

SCHEMBL4089129

Fc1ccccc1-c1nc(N2CCOCC2)c2ccccc2n1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.76
CYP1A2 P05177 6/20 0.73
CYP3A4 P08684 6/20 0.73
ALDH1A1 P00352 6/20 0.73
USP2 O75604 4/20 0.73
CLK4 Q9HAZ1 4/20 0.73
TSHR P16473 4/20 0.73
ALOX15 P16050 3/20 0.73
MAPK1 P28482 3/20 0.73
CYP2C19 P33261 2/20 0.73
CYP2C9 P11712 1/20 0.73
CASP7 P55210 1/20 0.73
CYP2D6 P10635 3/20 0.72
MAPT P10636 3/20 0.66
LMNA P02545 2/20 0.66
METAP1 P53582 1/20 0.65
SMN1; SMN2 Q16637 3/20 0.64
HTT P42858 2/20 0.63
TDP1 Q9NUW8 1/20 0.60
KDM4E B2RXH2 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1084817 0.88 HIF1A (0.92) HIF1ACYP1A2CYP3A4ALDH1A1USP2
SCHEMBL1083814 0.88 HIF1A (0.97) HIF1ACYP1A2CYP3A4ALDH1A1USP2
SCHEMBL1084484 0.88 CYP1A2 (0.60) HIF1ACYP1A2CYP3A4ALDH1A1USP2
SCHEMBL4091345 0.88 CYP1A2 (0.66) HIF1ACYP1A2CYP3A4ALDH1A1USP2
SCHEMBL1083986 0.88 CYP1A2 (0.60) HIF1ACYP1A2CYP3A4ALDH1A1USP2
SCHEMBL1084095 0.86 HIF1A (1.00) HIF1ACYP1A2CYP3A4ALDH1A1USP2
SCHEMBL1083928 0.84 HIF1A (0.76) HIF1ACYP1A2CYP3A4ALDH1A1USP2
SCHEMBL1083837 0.84 HIF1A (0.76) HIF1ACYP1A2CYP3A4ALDH1A1CLK4
SCHEMBL1083974 0.84 ABCB1 (0.78) HIF1ACYP1A2CYP3A4ALDH1A1USP2
SCHEMBL1084048 0.84 SMAD3 (0.78) HIF1ACYP1A2CYP3A4ALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 HIF1A 1496/4885CYP1A2 2477/4885CYP3A4 2113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.